Backblaze, Inc. Class A BLZE 深 滬
已收盤 02-06 16:00:00 美东时间
4.10
+0.100
+2.50%
華盛通- 最 高4.175
- 今 開4.10
- 成交量 71.36万股
- 最 低 3.965
- 昨 收 4.00
- 總市值 2.37亿
- 52周最高 10.8579
- 市盈率 靜 --
- 換手率 1.24%
- 52周最低 3.94
- 委 比 59.00%
- 總股本 5770.00万
- 歷史最高 36.50
- 量 比 0.81
- 振 幅 5.25%
- 歷史最低 3.50
- 每 手 1
- 風險率 1.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Security Tech Check-In: Analyst Insights From 12 Companies Ahead Of The 'Quiet Period'
Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mike Cikos.
2025-12-19 03:38
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Needham Maintains Buy on Backblaze, Lowers Price Target to $8
Needham analyst Mike Cikos maintains Backblaze (NASDAQ:BLZE) with a Buy and lowers the price target from $12 to $8.
2025-11-07 02:27
Backblaze shares are trading lower after the company reported Q3 financial results and issued Q4 sales guidance below estimates. Also, the company narrowed its FY25 sales guidance below estimates.
Backblaze shares are trading lower after the company reported Q3 financial resu...
2025-11-06 22:30
Backblaze Q3 Adj. EPS $0.03 Beats $(0.12) Estimate, Sales $37.200M Beat $36.931M Estimate
Backblaze (NASDAQ:BLZE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.12) by 124.59 percent. This is a 130 percent increase over losses of $(0.10) per share from the same
2025-11-06 20:20
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
2025-10-20 10:03
Oppenheimer Maintains Outperform on Backblaze, Raises Price Target to $11
Oppenheimer analyst Ittai Kidron maintains Backblaze (NASDAQ:BLZE) with a Outperform and raises the price target from $10 to $11.
2025-10-18 01:52
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
2025-08-08 09:34
Backblaze shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, raised its FY25 sales guidance, and announced a $10 million share repurchase program.
Backblaze shares are trading higher after the company reported better-than-expe...
2025-08-07 22:33
Backblaze Sees Q3 Sales $36.700M-$37.100M vs $36.588M Est
Backblaze (NASDAQ:BLZE) sees Q3 sales of $36.700 million-$37.100 million vs $36.588 million analyst estimate.
2025-08-07 19:04
